Sumnman-A tissue-isolated preparation of the P22 rat carcinosarcoma was used to investigate the tumour vascular response to angiotensin II (ATII). In particular. the relative importance of systemic and local tumour factors was assessed by comparing tumour vascular resistance during systemic administration of ATII and during administration directly into the tumour-supplying artery. The effect of hypervolaemia on tumour vascular resistance was determined as well as the effect of ATII on oxygen metabolism. Tumour vascular resistance was increased by ATII in a dose-dependent manner. The response was biphasic with an initial peak in resistance followed by a lower plateau phase. Systemic administration of ATII was more effective in increasing tumour vascular resistance than direct administration. This suggests that systemic administration is not causing any reopening of previously collapsed tumour blood vessels. Further evidence for this is that hypervolaemia caused no reduction in tumour vascular resistance and that there was no difference in oxygen extraction by tumours between groups treated with systemically and directly administered ATII. A heterogeneous distribution of ATII receptors in the P22 tumour is a more likely explanation for the known heterogeneity of blood flow response to ATII.
Intravenous infusion of angiotensin II (ATII) has been found to increase tumour blood flow relative to most normal tissues, and this has led to the concept of 'hypertension chemotherapy'. in which ATII is used to improve the relative delivery of chemotherapeutic agents to tumours (Susuki et al., 1981; Takematsu et al.. 1985; Noguchi et al., 1988; Kobayashi et al.. 1990 Kobayashi et al.. . 1991 Anderson et al., 1991; Kerr et al., 1992; Mutoh et al., 1992) . However, in absolute terms, ATII has been found to increase blood flow in some tumours (Tokuda et al.. 1990 ; Honr et al., 1991; Tanda et al., 1991) while decreasing it in others (Jirtle et al., 1978; Tozer and Shaffi, 1993) . A decrease in absolute tumour blood flow could compromise delivery of drug to tumour microregions. Whether tumour blood flow increases or decreases is dependent upon the balance between drug-induced hypertension ansing from systemic vasoconstriction and local vasoconstriction induced within the tumour itself (since blood flow = perfusion pressure . vascular resistance). Presumably, this balance varies with tumour type. although the underlying factors which determine response remain unclear. It is important to identify these factors in order to predict the response of a particular tumour to ATII.
We have previously found that ATII causes a significant increase in the vascular resistance of early generation, subcutaneous transplants of the P22 rat carcinosarcoma Tozer et al., 1994a) . We also found that the degree of vasoconstriction induced by ATII was dependent on pretreatment blood flow. That is, in whole tumours, vasoconstriction was greatest where blood flow to control tumours was highest and, in tumour sections, ATII caused a greater reduction in blood flow in the tumour periphery (pretreatment blood flow relatively high) than in the tumour centre (pretreatment blood flow relatively low). The cause of this differential effect was not clear. We proposed that (1) high-flow regions within tumours have a high density of receptors for ATII and or (2) there are collapsed blood vessels within low-flow tumour regions which reopen owing to ATII-induced hypertension. This paper is concerned with the second possibility.
The influence of hypertension on tumour blood vessel patency was investigated using a 'tissue-isolated' tumour Correspondence: G Tozer 
Materials and methods

Tumours
A transplanted rat carcinosarcoma. designated P22, was used for these experiments. Its origin and subcutaneous maintenance in BD9 rats have been described previously . Growth of the P22 tumour as a Itissueisolated' preparation in which the tumour microcirculation is derived from a single artery and vein has also been described previously (Tozer et al., 1994b) and is based on the method first described by Gullino and Grantham (1961) and Grantham et al. (1973) . This type of model has subsequently been used for characterising various aspects of the tumour microcirculation (Vaupel et al., 1985; Jain, 1989a.b. 1991; Graham et al., 1991; Eskey et al., 1993 Surgical preparation Two to three weeks after tumour implantation. when tumours reached 0.6-1.3 g. animals were prepared for experimentation. This preparation has been descnrbed previously (Tozer et al.. 1994b (Tozer et al.. 1994b) .
Once blood flow had stabilised. animals were either administered ATII or blood volume was modified as described below. Throughout these procedures tumour blood flow was monitored continuously, every 2 min. from the venous outflow. Systemic arterial blood pressure was continuously monitored via a pressure transducer (Gould) connected to the tail arterx catheter. Arterial blood haematocrits were measured before and during treatment using microcentrifugation of blood collected from the tail artery. Top-up doses of anaesthetic were administered intraperitoneally at regular intervals and rats were kept warm using a thermostaticallv controlled heating blanket and an angle-poise lamp. Surface tumour temperature was monitored using a thermocouple and maintained between 34.0 and 36.5°C throughout the experimental period.
Administration of angiotensin II Aliquots of angiotensin II. which had been made up to a concentration of 200 jig ml-' in distilled deionised water and stored at -20'C. were defrosted on each expenrmental day and were suitably diluted in 0.9% saline for infusion. Animals were designated for either systemic or local ATII administration. ATII at a concentration of 2 jg ml-' was infused into a catheterised tail vein for systemic administration. Dose rates from 10 to 1200 ng kg-' min-' were obtained by varying the infusion rate between 5 jI kg-' min and 600 1il kg-' min-'. ATII at a concentration of 0.5 jig ml-was infused into the cathetenrsed saphenous artery for direct administration to the tumour. Dose rates from 0.2 to 5.0 ng min-' were obtained by varying the infusion rate between 0.4 ILI min'-and 10.0 jIl min-'. Direct infusion rates never exceeded 10% of the total tumour blood flow. These dose rate ranges were chosen to approximate equivalent plasma concentrations of ATII for the two routes. Our previous measurements of blood flow to tissue-isolated tumours suggest that they receive approximately 0.6% of the cardiac output (assumed to be 50 ml min') (Tozer et ATII doses were increased in a stepwise manner for each rat and blood flow was allowed to stabilise for at least 10 mmn at each dose before further modification. After administration of the highest dose. ATII infusion was discontinued and rats were sacrificed by bolus intravenous injection of approximately 0.2 ml of Euthatal (RMB Animal Health). Tumours were excised and weighed so that tumour blood flow could be calculated as ml blood per g of tumour per minute (ml g-' min-').
.Modification of blood l olume Blood volume was increased in a stepwise manner for each rat by increasing the infusion rate of the donor blood above that of the venous outflow from the tumour. Infusion rate was adjusted between 100% and 300% of the outflow so that blood pressure gradually increased to approximately 130 mmHg over approximately 60 mn. This amounted to 5.3 ± 1.1 ml of donor blood added to the normal blood volume. A tendency for hypervolaemia to induce a haemoconcentration was corrected by adding extra plasma fluid to the donor blood. Rats were then sacrificed and tumours excised as described above.
Oxygen measurements
Blood samples (approximately 0.2 ml) were occasionally drawn from the catheterised tail artery or the venous outflow from the tumour for measurement of oxygen levels before and during the procedures described above. Blood sample containers were sealed and stored on ice before measuring oxygen partial pressure (po2) using a Corming 178 pH, 'blood gas analyser (Corming Medical). Measurements were made within 30 min of blood collection.
Oxygen concentration (co, in per cent) for each blood sample was calculated from po2 (in kPa) using the oxygen-haemoglobin dissociation curve for rat blood (Gray and Steadman. 1964 ) and 9.24 mmol 1 ' for the oxygencarrying capacity of blood. Oxygen availability (Ao. in lil gl mn 1) was calculated from co, of arterial blood and blood flow measurements from the venous outflow. Oxygen consumption (Qo in jil g-' min-') was calculated from the difference in co, between arterial and venous blood draining the tumour and blood flow measurements from the venous outflow. The fraction of oxygen extracted from the arterial blood as it passes through the tumour (oxygen extraction) was calculated from Qon . Ao. 
Results
Absolute levels of mean arterial blood pressure, tumour blood flow and tumour vascular resistance before (1) modification using systemically administered ATII. (2) modification using locally administered ATII and (3) modification using hypervolaemia are shown in Table 1 . There was no significant difference between the three groups for blood pressure or vascular resistance (analysis of variance. P = 0.11 and 0.10 respectively). However, pretreatment blood flow in the hypervolaemia group was significantly higher than in the other two groups (analysis of variance. P = 0.05). For this reason the hypervolaemia group was excluded from any between-group analyses of post-treatment parameters.
Continuous monitoring of blood pressure detected no obvious volume loading effects for systemic ATII. There was also no significant difference between arterial blood haematocrit measured before and during systemic administration of ATII (0.42 ± 0.01 and 0.40 ± 0.01 respectively). Tumour vascular resistance was increased by ATII in a dosedependent manner whether administered systemically or locally. However. the response was biphasic with an initial peak in resistance followed by a lower, plateau phase. The biphasic pattern was most apparent at the higher doses used. This is illustrated for local administration in Figure 1 .
Systemic administration of ATII to BD9 rats induced a dose-related rise in mean arterial blood pressure as reported previously . The increase in blood pressure was accompanied by an increase in vascular resistance in the tumours (Figure 2a) , which was similar to that found for the same tumours growing subcutaneously ). Blood flow during the plateau phase of the response was used for calculation of vascular resistance for this purpose. The increase in flow resistance was sufficiently large to overcome the tendency for tumour blood flow to increase in response to the rise in perfusion pressure, and the net result was a small decrease in tumour blood flow as shown in Figure 2b . Again, this effect is similar to that found for the subcutaneous site . administered ATII. Conversely. systemic administration of ATII produced a dose-dependent increase in vascular resistance which did not reach saturation at the doses used (Figure 3b ). Increases in plateau phase flow resistance above 250% were achieved via this route of administration.
Haematocrit dunrng hypervolaemia was 0.47 ± 0.02 compared with 0.44 ± 0.01 before modification. Figure 4 shows tumour vascular resistance vs perfusion pressure for rats in which blood pressure was modified using hypervolaemia. The effect of ATII-induced hypertension is also shown for companson. There is no indication of any reduction in vascular resistance as blood pressure is raised above normal levels.
Oxygen availability (Ao,) administered ATII. Theoretically, vasoconstriction following systemic administration could result from autoregulation in the tumour (an increase in flow resistance with increasing perfusion pressure which maintains blood flow constant over a large pressure range). However, local administration of ATII unequivocally demonstrated a direct response of the tumour blood vessels to the vasoconstrictive effects of the polypeptide.
A previous study has shown that, for systemic administration tumour vasoconstriction is of a similar order to that elicited in skeletal muscle and kidney . It is now clear that tumour vasoconstriction is dose dependent and that there is an initial peak in flow resistance which decays to a plateau value after the first minute or so of infusion. This biphasic response is a function of the local response of the tumour, although it is also observed during systemic administration. It implies that the effectiveness of chemotherapeutic drug administration during ATII infusion will be critically dependent upon timing. Recently, a similar biphasic response has been reported for isolated perfusions of the rabbit heart (Porsti et al., 1993) . These authors found that, at high ATII doses (> 10 nM), the flow resistance in the plateau phase was lower than the initial flow resistance, indicating vasodilatation. They concluded that the secondary vasodilatation was independent of the two primary endothelial autocoids, nitric oxide and prostacycin, and most likely reflected a desensitisation of the coronary artenral smooth muscle to the constrictor effect of ATII and an accumulation of vasodilatory metabolites such as adenosine during the constrictive phase. Desensitisation involves both reduction in number of ATII receptors and post-receptor mechanisms. Similar mechanisms are likely to be involved in the tumour response. No evidence was found for any ATII-induced reopening of previously collapsed tumour blood vessels which could explain our previous finding of a spatially heterogeneous tumour response to ATII Tozer et al., 1994a) . The P22 tumour was grown subcutaneously in that study rather than in the inguinal fat pad, and so we cannot discount the possibility that the present results are due to tissue isolation per se. However, the overall response to ATII was similar in the two sites, indicating some relevance of the inguinal tumours to the subcutaneous site.
The first piece of evidence against hypertension-induced reopening of collapsed tumour vessels is that systemic administration of ATII was more effective than local administration in increasing vascular resistance in the P22 tumour. If hypertension associated with systemic administra- tion of ATII were causing any reopening of previously collapsed vessels, this would tend to reduce the overall flow resistance in the tumour not increase it. The most probable explanation for our result is central stimulation of the sympathetic nervous system under systemic administration of ATII, possibly combined with enhancement of noradrenaline release into the bloodstream from sympathetic nerve fibres. These are both well-documented effects of exogenous ATII (Phillips, 1987) . There have been several reports of catecholamine-induced vasoconstriction in other tumour systems which make this a feasible explanation for our results (Weiss et al., 1979 (Weiss et al., , 1986 Tveit et al., 1987; Honr et al., 1993) . Secondly, hypervolaemia had no effect on tumour vascular resistance despite significantly increasing mean arterial blood pressure. A similar relationship between perfusion pressure and flow resistance has been found for ex vivo perfusions of the P22 tumour where systemic factors could not be involved in the response (Sensky et al., 1993 (Gullino, 1976; Vaupel et al.. 1987) . The increase in oxygen extraction and the tendency for oxygen consumption to decline during ATII administration was most likely a secondary effect of the decreased blood flow and therefore oxygen availability (Ao,) rather than a direct drug effect.
The use of anaesthesia is a possible artefact in these experiments which cannot be avoided. However, it does not preclude comparison of results with our earlier study in which the same anaesthetic agent was used Shaffi. 1993: Tozer et al.. 1994a ). In summary. we have found no evidence to support the proposal that ATII induces reopenmg of collapsed tumour blood vessels (Trotter et al.. 1991 : Tozer et al.. 1994a . Therefore. poorly perfused tumour regions may still be a problem under ATII-induced hypertension even when the mean absolute tumour blood flow is increased. A more likely explanation for our previous finding that ATII causes selective vasoconstriction at the tumour periphery is a heterogeneous distnrbution of receptors for ATII. A study into this possibility is now in progress. Differences in receptor number and subtype between different tumour types are also a likely explanation for the conflicting reports of ATII-induced blood flow changes. We have found that the response of the P22 vasculature to ATII is biphasic. It is possible that in some tumours with a different complement of ATII receptors. high doses of ATII could actually cause vasodilatation via desensitisation of the AT, receptor subtype and build-up of adenosine, as has been described in the heart (Porsti et al.. 1993) . Finally, we have found that the overall response of the tumour vasculature to systemically administered ATII is determined by direct vasoconstriction of blood vessels supplying the tumour and a further indirect vasoconstriction which is most probably associated with sympathetic stimulation. Pharmacological blockade of sympathetic stimulation in combination with ATII administration may therefore provide a means of reducing tumour vasoconstnrction and thus eliciting an increase in tumour blood flow.
